Paris, France-based Advent France Biotechnology (AFB), which focuses on early-stage European life sciences, has held a first closing of its second fund for a total of €86 million ($102 million).
The European Investment Fund and the Fonds national d’amorçage 2, managed on behalf of the French State by Bpifrance, participated in the fund, along with such corporate ventures as Boehringer Ingelheim Venture Fund, Pierre Fabre and a major Asian pharmaceutical company, family offices and AFB’s management.
Source: Firm announcement
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: